Revefenacin (TD-4208) is a novel, long-acting, and lung-selective muscarinic cholinergic receptor (mAChR) antagonist in development as a nebulized inhalation solution for the treatment of chronic obstructive pulmonary disease (COPD) patients. This study evaluated the pharmacology of revefenacin at human recombinant mAChRs and in airway tissues from rats, guinea pigs, and humans. At human recombinant mAChRs, revefenacin displayed high affinity (pK I = 8.2-9.8) and behaved as a competitive antagonist (pKI, apparent = 9.4-10.9) at the five human recombinant mAChRs. Kinetic studies demonstrated that revefenacin dissociated significantly slower from the hM 3 (t 1/2 = 82 minutes) compared to the hM 2 (t 1/2 = 6.9 minutes) mAChR at 37°C, thereby making it kinetically selective for the former subtype. Similarly, in functional studies, revefenacin-mediated antagonism of acetylcholine (ACh)-evoked calcium mobilization responses were reversed less rapidly at hM 3 compared to the hM 2 mAChR. In isolated tracheal tissues from rat and guinea pig and isolated bronchial tissues from humans, revefenacin potently antagonized mAChR-mediated contractile responses. Furthermore, the antagonistic effects of revefenacin in rat, guinea pig, and human airway tissues were slowly reversible (t 1/2 of 13.3, >16, and >10 hours, respectively). These data demonstrate that revefenacin is a potent, high affinity, and selective functional mAChR antagonist with kinetic selectivity for the hM 3 receptor and produces potent and long-lasting antagonism of mAChR-mediated contractile responses in rat, guinea pig, and human airway tissue. These data Abbreviations: ACh, acetylcholine; BA, beta2 agonist; CHO, chinese hamster ovary; COPD, chronic obstructive pulmonary disease; EFS, electrical field stimulated; FLIPR, fluorometric imaging plate reader; LAMA, long-acting muscarinic antagonist; mACh, muscarinic acetylcholine cholinergic receptor; MA, muscarinic antagonist; NMS, N-methyl scopolamine; T 1/2 , antagonist offset time or time required for contractile response to recover by 50%; t1/2, dissociation rate half-life; TD-4208, biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl] methylamino}ethyl)piperidin-4-yl ester.
suggest that revefenacin has the potential to be a potent once-daily dosed inhaled bronchodilator in COPD patients.
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| INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease characterized by progressive and persistent airflow limitation and is symptomatically manifested as dyspnea, chronic cough, and increased sputum production. 1 Tobacco smoking is the most common cause of COPD, with a number of other factors such as air pollution and occupational chemical hazards playing a minor role. COPD is currently one of the leading causes of death in the United States and the rest of the world. 1 The goal of pharmacological therapy in COPD is to alleviate symptoms, reduce the frequency and severity of exacerbations, and improve health status and exercise tolerance. 2 Inhaled bronchodilators, either mAChR antagonists (MA) or b 2 adrenoceptor agonists (BA), dosed alone or in combination with inhaled corticosteroids serve as the mainstay of COPD pharmacotherapy. 2 Inhaled MA evoke bronchodilation by suppressing the elevated cholinergic bronchoconstrictor tone mediated by mAChRs localized on parasympathetic ganglia and airway smooth muscle. 3 Based on duration of bronchodilation in patients, inhaled MA are classified as either shortacting muscarinic antagonists (SAMAs) or long-acting muscarinic antagonists (LAMAs). 4 SAMAs, which include molecules such as ipratropium, are dosed three to four times daily. LAMAs include twice-daily dosed drugs, such as aclidinium and glycopyrronium, or once-daily dosed drugs such as tiotropium and umeclidinium.
Inhaled therapies for COPD are marketed as either dry-powder inhalers, pressurized metered dose inhalers or nebulizers. Although nebulizers can be less portable than hand-held inhalers, they are the preferred delivery device for a proportion of COPD patients who have severe disease, frequent exacerbations, those with physical and/or cognitive limitations 5 and those with compromised peak inspiratory flow rates. 6 At present, a once-daily dosed nebulized LAMA is not commercially available for COPD patients.
Revefenacin (TD-4208; biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-
carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester) ( Figure 1 ) is an investigational LAMA, in late-stage development as a nebulized inhalation solution, that was designed to produce long-acting bronchodilation, consistent with once-daily dosing, and with a high degree of lung-selectivity to avoid systemic antimuscarinic adverse effects such as dry mouth, urinary retention, and constipation. [7] [8] [9] [10] Following inhalation dosing to rats and dogs, revefenacin produced potent protection against the bronchoconstrictor response to ACh or methacholine (MCh). 10 In both species, the bronchoprotective effect was long-acting (≥24 hours) and comparable in duration to tiotropium. The functional lung-selectivity index of revefenacin in rats, derived from its relative potency to antagonize muscarinic bronchoconstrictor versus sialagogue effects, was superior to that of tiotropium after either a single dose or seven repeated inhaled doses. Here, we report the in vitro pharmacological properties of revefenacin at recombinant mAChRs and in rat, guinea pig, and human airway tissues expressing native mAChRs. The findings from these translational studies are consistent with emerging clinical data showing 24 hours bronchodilatory activity of nebulized revefenacin in COPD patients. 7, 9 2 | MATERIALS AND METHODS
| Materials
[N-methyl- 
| Studies with animals and human tissue
All animal studies were reviewed and approved by the Institutional In static studies, paired tissues were exposed to either compound or vehicle for 120 minutes before cumulative concentrationresponse curves to CCh were generated. CCh-induced responses for each tissue were expressed as a percentage of histamine for the duration of the experiment. Upon reaching a sustained contraction isoproterenol (10 lmolÁL
À1
) was administered to maximally relax the tissue, and this change served as a reference. Isoproterenol exposure was halted and the carbachol-induced tension was allowed to recover. Test compounds were infused at a single concentration per tissue for a period of 6 hours until a sustained level of inhibition was attained. Infusion of compound was halted and the CCh-induced tension was allowed to recover for 10 hours. Antagonist-induced inhibition of the CCh-induced contraction was expressed as a percent of the isoproterenol reference response.
| Off target activities
Revefenacin was evaluated in a panel of 81 receptors, enzymes, and channels at 1 lmolÁL
À1
, a concentration that is >5000-fold over its affinity for the hM 3 receptor and the plasma exposure (C max ) at human efficacious doses of 88 and 175 lg. 13 The standard assays were performed at Cerep (Le Bois l'Evêque -B.P. 1 -86600 Celle L'Evescault, France). Revefenacin was also tested separately in a concentration-response curve study in an H 1 radioligand binding assay and in a 5-HT4 agonist assay.
| Data analysis and statistics
Concentration-effect curves were analyzed through iterative curve fitting to a logistic equation using GraphPad Prism 5.0. 16 In reversibility studies, the offset time (t 1/2 ), following removal of the antagonist, was determined by measuring the time required for response to recover by 50%.
Whenever appropriate, data were analyzed statistically using a unpaired t-test with P < .05 considered as significant. 
| Off target activities
Drug-related side effects are often the result of compound activities at undesired targets. To check for possible off-target effects, revefenacin was screened for activity in a panel of 81 receptors, enzymes, and channels at a concentration of 1 lmol L À1 (a concentration that was >5000-fold over its hM 3 K I ). Revefenacin To determine dissociation rates, membranes prepared from cells expressing hM 2 or hM 3 receptors were incubated with tritium-labeled compounds, followed by the addition of 10 lmol L À1 atropine at 37°C. Membranes were then filtered at various times after atropine addition. To determine the association rate, tritium-labeled compounds, and membranes prepared from cells expressing hM 2 or hM 3 receptors were incubated together for varying lengths of time at 37°C prior to rapid filtration. Data are reported as mean AE SD; n = 3-7. ) showed approximately 70% and 40% recovery from the maximum inhibitory effect, respectively, after 17 hours of continuous tissue perfusion with drug-free buffer, whereas tissues exposed to ipratropium (10 nmolÁL
À1
) showed approximately 60% recovery of ACh contractile activity after only 4 hours of continuous perfusion ( Figure 4B ). The t 1/2 values were estimated to be 13.3 AE 3.1 hours for revefenacin, >17 hours for tiotropium which was significantly (P < .05) lower than that of ipratropium (1.6 AE 0.8 hours). In antagonist washout studies using IC 90 concentrations, the inhibitory effects of atropine (100 nmolÁL
) were rapidly reversed (t 1/2 = 1.3 hours), whereas those of revefenacin (30 nmolÁL
) and tiotropium (3 nmolÁL
) persisted for significantly (P < .05) longer periods (t 1/2 = >16 and >20 hours, respectively) ( Figure 5B ).
| Antagonism of carbachol-evoked contraction of human isolated bronchial tissue: potency and offset time
In static tissue bath studies, revefenacin (1-1000 nmolÁL À1 ) caused dextral shifts of the CCh concentration-response curves in human Apparent inhibition constants for revefenacin and other antagonists were determined using agonist (ACh) stimulated calcium mobilization assays using CHO-K1 cells expressing hM 1 , hM 3 , hM 4 -G a16 , cM 5 mAChRs. Apparent inhibition constants for revefenacin and other antagonists were determined using agonist (ACh) stimulated [ In superfusion washout studies, none of the tissues treated with revefenacin (10-100 nmolÁL À1 ) recovered to 50% of the 1 lmol L
À1
CCh contraction (t 1/2 > 10 hours) following 10 hours of perfusion with antagonist-free buffer ( Figure 6B ). The t 1/2 for 1 and 10 nmolÁL À1 tiotropium was 6.3 and >10 hours, respectively, and for 10 nmolÁL À1 ipratropium, it was 2.9 hours. (Figure 6B ). No statistics could be performed on this data because of the small number of donors.
| DISCUSSION
Revefenacin was designed to be a once-daily inhaled lung-selective LAMA and is being developed for COPD patients who require or prefer nebulized therapy. The present studies have shown that revefenacin is a high affinity competitive antagonist at human recombinant mAChRs with kinetic functional selectivity for M 3 over M 2 mAChRs and a potent, slowly reversible antagonist in rat, guinea pig, and human airway tissues expressing native mAChRs.
In a previous study, we demonstrated that inhaled revefenacin produced potent protection against ACh or MCh evoked bronchoconstriction in dogs and rats. 10 In this study, we investigated the antagonist potency and offset time in isolated tracheal tissues from rat in order to gain mechanistic insight into the long-acting bron- We also sought to translate the biological effects of revefenacin in rats and guinea pigs by characterizing the pharmacological effects of revefenacin at both human recombinant mAChRs and in isolated human airway tissues. In equilibrium competition radioligand binding studies, revefenacin, like tiotropium, and glycopyrrolate, demonstrated subnanomolar affinity for all five human mAChR subtypes, including M 2 (pK I = 9.5) and M 3 (pK I = 9.7) mAChRs, the two key receptors involved in airway smooth muscle tone and contraction. 3 The affinity estimates obtained for ipratropium, tiotropium, and glycopyrrolate were consistent with those reported previously. 18, 19 The rank order of potency was tiotropium > revefenacin = glycopyrrolate > ipratropium. The high affinity of revefenacin for human mAChRs was replicated in equilibrium saturation binding studies that yielded a K D range of 0. M 2 receptor half-life = 6.6 and 6.0, respectively). Although the kinetic behavior of ipratropium was not evaluated in this study, it has been reported to dissociate rapidly from both hM 2 and hM 3 receptors. 22 Functional reversibility studies were conducted at human recom- In the human bronchus, revefenacin potently and insurmountably antagonized the carbachol-induced contractile responses. In superfusion drug washout studies, the antagonistic effects of ipratropium (t 1/2 = 2.9 hours) were rapidly reversible, whereas those of revefenacin and tiotropium persisted for several hours (t 1/2 of >10 hours at the highest concentration tested). These results imply that the slow functional reversibility of the antagonistic effects of revefenacin observed in human recombinant M 3 mAChRs also translates to native mAChRs expressed in human airway tissues. It is interesting to note that despite having an hM 3 dissociation t 1/2 that is 2.8-fold shorter than that of tiotropium, the reversibility offset times in human bronchus of revefenacin was comparable to that of tiotropium suggesting that factors other than slow receptor off-rate also contribute to its duration at the tissue level.
In summary, the present studies illustrate that revefenacin produces potent and long-lasting antagonism of mAChR-mediated contractions of rat and guinea pig tracheal tissues. These data provide an explanation for the potent and long-acting bronchoprotective effects previously reported in rats after inhalation dosing. More importantly, the high affinity and selectivity of revefenacin for human recombinant mAChRs and its potent and long-lasting antagonism of mAChR-mediated contraction of human bronchial tissues provide confidence in the translational of preclinical findings to humans. Indeed, clinical Phase 2 dose-range studies have demonstrated sustained 24 hours bronchodilation in COPD patients following once-daily dosing. 7, 9 Phase 3 studies with nebulized revefenacin are being conducted to confirm its long-acting bronchodilator effects and safety in COPD patients. Furthermore, recently reported Phase 3 efficacy studies 23, 24 continue to support the safety and efficacy of revefenacin as a potential new therapeutic option for patients with COPD who may benefit from treatment with a once-daily, nebulized bronchodilator.
